Skip to main content

Repurposed agents in the Alzheimer’s disease drug development pipeline

A Correction to this article was published on 21 August 2023

This article has been updated



Treatments are needed to address the growing prevalence of Alzheimer’s disease (AD). Clinical trials have failed to produce any AD drugs for Food and Drug Administration (FDA) approval since 2003, and the pharmaceutical development process is both time-consuming and costly. Drug repurposing provides an opportunity to accelerate this process by investigating the AD-related effects of agents approved for other indications. These drugs have known safety profiles, pharmacokinetic characterization, formulations, doses, and manufacturing processes.


We assessed repurposed AD therapies represented in Phase I, Phase II, and Phase III of the current AD pipeline as registered on as of February 27, 2020.


We identified 53 clinical trials involving 58 FDA-approved agents. Seventy-eight percent of the agents in trials had putative disease-modifying mechanisms of action. Of the repurposed drugs in the pipeline 20% are hematologic-oncologic agents, 18% are drugs derived from cardiovascular indications, 14% are agents with psychiatric uses, 12% are drug used to treat diabetes, 10% are neurologic agents, and the remaining 26% of drugs fall under other conditions. Intellectual property strategies utilized in these programs included using the same drug but altering doses, routes of administration, or formulations. Most repurposing trials were supported by Academic Medical Centers and were not funded through the biopharmaceutical industry. We compared our results to a European trial registry and found results similar to those derived from


Drug repurposing is a common approach to AD drug development and represents 39% of trials in the current AD pipeline. Therapies from many disease areas provide agents potentially useful in AD. Most of the repurposed agents are generic and a variety of intellectual property strategies have been adopted to enhance their economic value.


Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with a rising prevalence due to the global increase in the aging population [1]. It is estimated that one in 85 people will be living with an AD diagnosis by 2050 [2]. An urgent need exists to identify effective interventions that will combat this disabling and ultimately fatal disease. Attempts to find new therapies for AD have been made by academic centers and biopharmaceutical companies: identifying new chemical entities, optimizing them for human use, and investigating their effects in clinical trials. However, the lack of an approved drug for AD by the Food and Drug Administration (FDA) since 2003 demonstrates the complexity of this objective [3].

Efforts to produce new treatments for AD are focused primarily on identifying new compounds that may improve symptoms, slow disease progression, delay the onset, or ultimately prevent the disease. An alternative approach to advancing new treatments is the development of drugs approved for a non-AD-related indication that may impact the biology of AD through on-target or off-target mechanisms. This repurposing strategy has succeeded in other conditions and has promise for AD since many FDA-approved agents exhibit AD-relevant effects evident through in vitro, animal, epidemiologic, and observational studies [4,5,6,7,8,9].

To better understand repurposing in the AD drug development process, we conducted an analysis of all ongoing AD clinical trials involving FDA-approved drugs. We analyzed trial data reported on, a comprehensive US government database with mandated registration of all clinical trials conducted within the US. We examined all currently ongoing trials that involved repurposed agents and compared this to all drugs in the AD pipeline [10,11,12,13,14]. We also compared ongoing trial activity of repurposed AD drugs as reported on the European Union Clinical Trials Register (EUCTR). Our goal was to examine how repurposing efforts in the AD drug pipeline compares to overall drug development activity in the United States (US) and international pipelines and to provide insight into repurposing as a drug development strategy.


This study is based on the activity of clinical trials reported on By US law, all clinical trials conducted within the US must be registered within 21 days of the enrollment of the first participant [15, 16]. is a comprehensive and valid data source for the study of clinical trials conducted in the US. Most, but not all, non-US trials are registered on; Phase I trials conducted outside the US are often not registered and our findings may underrepresent the agents populating global Phase I efforts.

We used a previously constructed trial database that included the data of interest [10,11,12,13,14] and report on all trials currently testing repurposed agents in Phases I, II, and III. The results reported here are based on trials registered on as of February 27, 2020. We used labeling and included trials that were recruiting, active but not recruiting, enrolling by invitation, and not yet recruiting. We do not include trials of stem cell therapies among the interventions reviewed.

Our focus on repurposed agents places an importance on drugs with an FDA-approved indication(s). Agents were considered to be repurposed based on the information recorded on Drugs@FDA (, a US government database containing drug products approved since 1939 that is updated daily [17]. The approved use for each drug was determined by the most recent label provided by Drugs@FDA. Some drugs have more than one FDA-approved indication, and this is noted.

Agents were further classified based on the therapeutic area for which each drug is prescribed as determined by its approved indication. Based on this classification, we examined the therapeutic area origin of agents being studied across all AD trials. Some agents are being studied in multiple ongoing trials; we defined these agents as “unique” agents. Varieties of a particular compound seen in two or more trials (i.e., dosing, routes of administration) were noted.

Some trials are investigating multiple repurposed drugs in separate treatment arms (e.g., telmisartan vs perindopril) or in combination (e.g., losartan, amlodipine, and atorvastatin as a single treatment). For the purposes of this study, we treat the former as separate therapeutic trial agents; the latter is considered a single agent with respect to its clinical trial because the intent of the trial is to study the effects of the fixed combination as a single therapy.

A drug’s putative mechanism of action (MOA) in AD was determined from the information on or from a comprehensive review of the literature for the specific agent. We grouped the mechanisms into disease-modifying therapies (DMTs) or symptomatic agents. The latter is further divided into cognitive-enhancers or those that address neuropsychiatric and behavioral symptoms. We identified an agent as a DMT when the purpose of the intervention was to modify the underlying disease biology and to delay the onset or slow the progression of the disease. DMTs were divided into those targeting amyloid-related targets, tau-related mechanisms, and those with “other” mechanisms (i.e., neuroprotection, anti-inflammation, metabolic effects). The distinction between symptomatic agents and DMTs can be arbitrary and some agents may have both properties. For the purposes of this study, we chose what appears to be the principal MOA.

We retrospectively compare current repurposing trial data with historical data from previous AD pipeline reviews, starting from 2016 onward [10,11,12,13,14]. We used identical methodology to ascertain inclusion of clinical trials as detailed above.

Our study analyzes parallel activity between the US and European AD pipelines using trial information reported on the EUCTR. This public register enables access to data from the European Union Drug Regulating Authorities Clinical Trials (EudraCT) database, which contains protocols and results of studies conducted in the European Union (EU) or the European Economic Area (EEA). We used EUCTR to query Phase I, Phase II, and Phase III AD trials with ongoing status recorded as of February 27, 2020. We distinguish clinical trials exclusive to the EU/EEA from overlap studies running concurrently in the US.



There are 58 total repurposed drugs in 53 clinical trials as reported on We identified 15 agents in 12 trials in Phase III, 33 agents in 32 trials in Phase II, and 10 agents in nine trials in Phase I. Of these trials, six agents were in Phase II/III trials and two agents were in Phase I/II trial. Several trials have more than one agent; some drugs are being studied across multiple trials.

Analysis of the FDA-approved indications of all repurposed drugs in the pipeline showed that 20% are hematologic-oncologic agents, 18% cardiovascular agents, 14% are psychiatric agents, 12% are antidiabetic treatments, 10% are drugs for other neurologic disorders, and the remaining 26% of drugs are derived from other therapeutic area categories. Repurposed psychiatric drugs in Phase III trials represent 50% of all agents being assessed for the treatment of neuropsychiatric symptoms in AD. Half of all cardiovascular agents under study are in Phase III trials. The majority of the pipeline’s hematologic-oncologic, antidiabetic, and neurologic agents are in Phase II trials (70, 67, and 67%, respectively). Phase II has more repurposed agents than Phase I and Phase III combined. Figure 1 shows the classification of all repurposed drugs by FDA-approved indications within their respective clinical phases.

Fig. 1
figure 1

Classification of repurposed agents by their FDA-approved indications ( as of February 27, 2020)

Review of the AD-related MOAs of all agents shows that 78% are being developed as DMTs, 16% are symptomatic agents addressing neuropsychiatric and behavioral changes, and 7% are cognitive enhancers (Table 1). Escitalopram is being investigated separately as a cognitive enhancer in Phase I and as a neuropsychiatric agent in Phase III. Among DMT trials, the agents are derived primarily from hematologic-oncologic, cardiovascular, and antidiabetic indications (26, 18, and 16%, respectively). In contrast, symptomatic agents are derived mostly from treatments addressing psychiatric illness (50%). Figure 2 shows the repurposed agents’ AD-related MOAs.

Table 1 Alzheimer’s disease-related mechanisms of action of repurposed agents in the pipeline ( as of February 27, 2020)
Fig. 2
figure 2

Percentage of repurposed agents currently under study by mechanisms of action ( as of February 27, 2020)

Unique repurposed agents

There are 50 unique repurposed drugs (defined as drugs represented at least once from the 58 total in the pipeline) that are under study among all AD pipeline trials. Twenty percent are hematologic-oncologic agents, 18% are cardiovascular agents, 14% are psychiatric agents, 12% are antidiabetic agents, 10% are neurologic drugs, and the remaining 26% of treatments were used in other categories. Figure 3 provides a graphical summary of the classifications of all unique repurposed agents represented in the current AD pipeline.

Fig. 3
figure 3

Classification of the therapeutic areas of repurposed agent currently under study ( as of February 27, 2020)

The agent most represented among all trials is levetiracetam (four Phase II trials, one Phase III trial). Telmisartan, montelukast, escitalopram, and valacyclovir are each in multiple Phase II and Phase III trials. A propriety low-dose formulation of levetiracetam (AGB101, which is 1/15th of the original dose) is being investigated in Phase II and Phase III trials.

Phase III

In Phase III trials, there are 15 repurposed agents in 12 trials (Table 2); this represents one-third of all Phase III trials in the AD pipeline [14]. These include eight DMTs, one cognitive-enhancer, and six agents addressing behavioral symptoms. Among DMT agents, one had amyloid-related targets, five had anti-inflammatory MOAs, four were considered metabolic, and two were neuroprotective agents.

Table 2 Repurposed agents currently in Phase III in the Alzheimer’s disease development pipeline (as of February 27, 2020)

Therapeutic areas represented among the repurposed agents included five cardiovascular drugs, four with psychiatric indications, three neurological drugs, one hematologic-oncologic agent, one antidiabetic agent, and one pulmonary agent. Among these drugs, sedative-hypnotics were the most common.

In Phase III, there were two prevention trials with cognitively normal (preclinical) participants; three trials of patients with prodromal AD/mild cognitive impairment (MCI); five trials of patients with mild to moderate AD; and two trials of patients with mild to moderate/severe AD.

Phase II

Phase II of the AD pipeline has 32 trials involving 33 repurposed agents (Table 3); this is 44% of all AD trials in Phase II [14]. Of the repurposed agents, there were 27 DMTs, one cognitive-enhancing agent, and three drugs for behavioral symptoms. Among the DMTs, three involve amyloid targets, one addresses tau-related targets, one has a mechanism relevant to both amyloid- and tau-related targets, and 22 have other MOAs (e.g., neuroprotection, metabolic, or anti-inflammatory). Of the symptomatic agents, all four are neurotransmitter-based.

Table 3 Repurposed agents currently in Phase II in the Alzheimer’s disease development pipeline (as of February 27, 2020)

Therapeutic areas of Phase II repurposed agents comprise hematologic-oncologic agents (seven), neurologic drugs (six), cardiovascular drugs (four), antidiabetic agents (four), and other classes (e.g., cannabinoid, alkaloid; 12 total). Anticonvulsants were the most represented drug class in Phase II.

There is one prevention trial; 19 trials of patients with prodromal/MCI or prodromal/mild-AD; 11 trials in mild-moderate AD; and one trial of patients with mild-moderate/severe AD. Among DMT trials, there is one prevention trial with cognitively normal participants, 17 for prodromal/mild AD, and eight for participants with mild-moderate AD.

Phase I

There are ten repurposed agents among nine Phase I trials (Table 4), which is 33% of Phase I trials in the pipeline [14]. Of these, there are eight DMTs and two cognitive enhancers. No agents addressing neuropsychiatric symptoms are represented in the Phase I pipeline. Of the DMTs in Phase I, one agent is directed at amyloid-related targets while seven have other MOAs (e.g., neuroprotection, metabolic, or anti-inflammatory). No tau-related repurposed agents are under investigation in Phase I of the current pipeline.

Table 4 Repurposed agents currently in Phase I in the Alzheimer’s disease development pipeline (as of February 27, 2020)

In Phase I, repurposed agents include three psychiatric drugs, two hematologic-oncologic agents, one cardiovascular drug, one antidiabetic agent, and three agents in other drug classes (e.g., anti-inflammatory drug, infectious disease agent).

Trial sponsors

Across all trials of repurposed agents, 9% are sponsored by the biopharma industry, 79% by Academic Medical Centers (with funding from the National Institutes of Health, industry, and/or other entities such as a consortium or a philanthropic foundation), and 11% by others. Table 5 shows sponsors for each phase of development.

Table 5 Trial sponsor for repurposed agents by phase of drug development (as of February 27, 2020)

Repurposed agents in the pipeline from 2016 to 2020

Table 6 summarizes the number of repurposing trials in previous annual AD pipeline reports [10,11,12,13,14]. Since 2016, the number of trials involving repurposed agents has increased by 89%. The number of trials has grown each year, with the greatest rate of increase occurring between 2019 and 2020 (23% growth). Between 2016 and 2020, repurposed DMT trials have increased 180%; repurposed trials focused on symptom-reduction have decreased by 67%.

Table 6 Repurposing agent trials between 2016 and 2020

Phase I trials of repurposed agents have increased 125% since 2016; Phase II and Phase III trials have risen 88% and 71%, respectively. DMT trials of repurposed agents currently make up 79% of all repurposed agents in the current pipeline (up from 54% in 2016; Fig. 4).

Fig. 4
figure 4

Repurposing trials over time in the Alzheimer’s disease drug development pipeline (2016–2020)

Repurposed agents in the European AD pipeline

Out of 138 AD trials with an ongoing status registered with the EUCTR, we identified 14 trials involving 14 FDA-approved drugs (Table 7). Eleven of these were dual-registered with the US and EU/EEA databases. Five trials were in Phase III and nine were in Phase II. Six had a completed or terminated status when compared to the information listed on Three trials were registered exclusively with the EUCTR: epoetin alfa, levodopa-carbidopa, and cannabidiol.

Table 7 Repurposing agents currently in the European Alzheimer’s Disease development pipeline (as of February 27, 2020)

There were six DMTs, five cognitive-enhancing agents, and three drugs addressing neuropsychiatric symptoms among the repurposed agents. Therapeutic areas represented included four neurologic drugs, two hematologic-oncologic agents, one drug with pulmonary indications, and one antidiabetic agent.


Drug repurposing provides the unique opportunity to significantly shorten the development period of a therapeutic candidate for AD. These agents have been extensively assessed for pharmacokinetic properties and toxicities normally required in nonclinical and Phase 1 stages of development. Over half of all agents fail in development for these two reasons, and repurposing circumvents these challenges [18]. FDA-approved drugs have already undergone human trials, and safety, efficacy, and adverse event profiles are known. The results of previous trials may suffice to bypass nonclinical stages and earlier clinical phases of study; this has the advantage of foregoing the financial and time-costs associated with a drug development program. Total costs for developing a new agent may be as high as $5.7 billion with $1.66 billion required for non-clinical studies and $1.19 billion for Phase I [19]. Total development costs may be reduced by 50% compared to the cost of developing a new chemical entity.

FDA-approved agents have been optimized for the original indication. Different doses might be needed, and different adverse event profiles may occur in an AD population compared to other populations for which the agent was originally developed. Some steps in the development process might be repeated to account for these contingencies. Repurposed agents are often generic and have limitations on intellectual property rights that compromise attracting investments that could propel their development [20].

Examination of the repurposed agents in the current AD pipeline revealed that DMT trials were chiefly based on agents derived from hematologic-oncologic (tyrosine kinase inhibitors), cardiovascular (angiotensin II receptor antagonists, angiotensin-converting enzyme inhibitors), and neurologic indications (anticonvulsants), as well as diabetes. Growing evidence supports the association between the key pathologic changes these drugs target and the underlying biology of AD [21,22,23,24]. The links between dementia-related symptoms and the abnormal activation of tyrosine kinase pathways, cardiovascular disease, and impaired insulin sensitivity are reflected by the presence of these agents in the pipeline of repurposed drugs. With increasing knowledge of these processes in AD, repurposing may comprise a precision medicine approach to AD therapeutics [25]. A preponderance of psychiatric compounds comprise the symptomatic agent class, and the vast majority (including some non-antipsychotics) are aimed at alleviating AD-associated agitation. This may show a priority in the field to identify treatments for a distressing aspect of AD for patients and caregivers. These trials were facilitated by the development of new diagnostic criteria for agitation that assist in patient identification and outcome determination [26].

Certain repurposed candidates may offer therapeutic benefits without directly engaging AD targets. Reduced cerebral blood flow correlates with AD pathology [27]. A pilot study has suggested that the antiplatelet agent, cilostazol (NCT02491268), may slow cognitive decline through pleiotropic effects, including regional enhancement of cerebral perfusion [28,29,30]. Some drugs target the role of neuroinflammation in AD: inflammation affecting the function of the blood-brain barrier is a component of interest in two trials of montelukast (NCT03402503, NCT03991988, [31, 32]). Trialists studying rifaximin (NCT03856359) posit an improvement in cognitive function by reduction in pro-inflammatory cytokines and ammonia levels [32].

Repurposing agent trials make up 39% of the total AD pipeline in 2020 (compared to 24% in 2016). Phase II has the largest number of trials—in both repurposing trials and in the overall pipeline (60 and 55%, respectively). This likely results from entry of repurposed agents directly into Phase II or Phase I/II. DMT trials comprise approximately 79% of the 2020 AD pipeline, compared to 75% when looking at the subset of repurposed agents. Although amyloid is the most common specific target in Phase II and Phase III DMT trials overall, the majority of repurposed DMTs involve tau targets.

Forty-six percent of all AD trials are funded at least in part by biopharmaceutical industry sources. In contrast, the majority of repurposed trials (79%) receive partial or complete funding from Academic Medical Centers and only 9% are sponsored by the biopharmaceutical industry. This reflects the challenges of obtaining intellectual property protection for repurposed agents that discourage for-profit enterprises from exercising this development pathway. The observation emphasizes the importance of Academic Medical Centers and federal and philanthropic funding in the AD drug development ecosystem.

A variety of strategies are being assessed to try to secure intellectual property positions for repurposed agents. Using different doses relative to an agent’s original indication is one approach and depends on the drug exposure required for each indication. This strategy is exemplified by the HOPE4MCI study (NCT03486938), which is using one-tenth of the dose of levetiracetam used for anticonvulsant purposes. Another approach is the use of novel formulations of an agent. Insulin glulisine (NCT02503501) is a rapid-acting version of the insulin; a long-acting form (NCT01595646) was developed for trials in AD [33]. Montelukast is being investigated as a cognitive enhancer in two separate trials (NCT03991988, NCT03402503) using an oral tablet and a buccal film patch, respectively. This highlights the opportunity to develop novel delivery mechanisms for repurposed agents as a means of enhancing efficacy and securing intellectual property rights.

The marked increase in repurposing may reflect the recent efforts aimed at elucidating the benefits of repurposing as a strategy in AD drug development [7, 34]. Funding from federal, advocacy, and philanthropic sources disproportionately support trials of repurposed agents and this may have driven the increase in repurposing. Repurposing may have been accelerated by advances in methodologies that are being used to identify AD-efficacious pharmaceuticals that include phenotypic or high content screening, in silico techniques, bioinformatic or computational strategies, and medical genetic-based approaches [9, 35,36,37,38,39]. Electronic health records may provide evidence of beneficial effects on AD or other neurodegenerative disorders by therapies approved for other indications and represent another means for discovering repurposing agents [39, 40]. The effects of long-term exposure to these agents, however, may not be recapitulated in the 18–24 months of most current AD trials.

Between 2016 and 2020, 20 trials of repurposed agents reached a “completed” status while four were “terminated” for various reasons. Post hoc analysis of a pilot Phase II Metformin study (NCT01965756) found the agent to be safe and well-tolerated, with improvements in executive function [41]. In another study, a short course of NewGam 10% IVIG (intravenous immunoglobulin; NCT01300728) given during the mild cognitive impairment (MCI) stage of AD decreased brain atrophy and ameliorated cognitive decline, but beneficial effects did not persist after 2 years [42]. A phase I study (NCT01780519) found that lorazepam may unmask pre-symptomatic cognitive dysfunction in individuals with underlying genetic risk for AD [43]. Primary outcome analyses of the NILVAD study (NCT02017340) failed to show any treatment benefit with nilvadipine when compared to the matched placebo population, though the drug was found to be safe and well-tolerated [44]. The AMBAR study by Grifols (NCT01561053) offers a novel approach to potential AD treatment via therapeutic albumin replacement with or without immunoglobulin [45]. Outcome analyses revealed a statistically significant 61% decrease in progression of moderate AD who received treatment. None of the trial “failures” results from problems associated with safety or tolerability, which may be indicative of the extensive studies repurposed agents have already undergone.

A single repurposed compound may target different outcomes; escitalopram is being studied simultaneously in trials for agitation and for improvements in cognition (NCT03108846, NCT03274817). Combinations of FDA-approved drugs represent another approach to repurposing; ALZT-OP1 (NCT02482324) uses a two-part combination of repurposed agents—a mast-cell stabilizer (cromolyn) and the non-steroidal anti-inflammatory agent ibuprofen. A combination of losartan, amlodipine, and atorvastatin is a combination trial (NCT02913664) involving repurposed agents to address the vascular dimensions of AD.

We assessed repurposing in the EUCTR and compared it to the analyses of Using the same criteria used to query the US governmental database, we found that repurposing trials make up approximately 10% of all ongoing EU/EEA AD trials (in contrast to 39% in the US AD pipeline). Similar to the US pipeline, the majority of trials (64%) are in Phase II and involve DMT agents (43%). The majority of agents identified in the EU/EEA trials were among the agents identified in; only three trials were unique to the EUCTR.

Some major discrepancies were encountered when comparing both trial registers. Six of the 14 EUCTR trials, or 43%, were found to have a “completed” or “terminated” status on (Table 7). Inaccurate reporting of dual-registered trials on EUCTR is a prevalent issue [46], which may in part reflect the register’s reliance on sponsors to manually enter study results onto the EudraCT database. Suboptimal completion of RCT protocols and results may lead to overestimates of trial activity [47,48,49,50].

Repurposing is to be distinguished from developing extended indications for a proprietary agent as part of life-cycle management. Pimavanserin, for example, is approved for the treatment of hallucinations and delusions in Parkinson’s disease psychosis; an extended application for dementia-related psychosis is currently being developed for several dementia syndromes [51, 52]. Likewise, suvorexant is approved for insomnia and completed a successful trial for insomnia in AD and the labeling of the compound has been adjusted to include this information. Brexpiprazole is approved for the treatment of schizophrenia and as adjunctive therapy for major depressive disorder; it is being assessed in the AD pipeline as a therapy for agitation [53]. These programs represent extensions of indications and not repurposing.

Repurposing can be distinguished from repositioning in which a non-approved agent in a sponsor’s development program changes from one indication to another because disease-related, compound-related, or commercial circumstances suggest that success in further development may be more likely in one condition than another [54, 55].


There are limitations of the current analyses. Because not all Phase I trial activity may be recorded in the database, our data may underestimate the actual number of trials in this phase. Estimates of drugs designated as DMT versus symptomatic agents may be equivocal depending on what is perceived as an agent’s principle MOA. We stopped entering new data into our database at a time that allowed submission, peer review, and publication (final data collection stopped on February 27, 2020) and there may be newer trials or changes to current trials not reflected in this document.


In summary, repurposing is a promising avenue for AD drug development, comprises a substantial part of the current AD pipeline, and is increasing in absolute numbers of agents and as a proportion of the pipeline. Repurposing may reduce drug development costs by up to 50% and accelerate times lines for progression in the pipeline. Repurposing draws on development programs from numerous other indications. Repurposing is an important part of the current AD drug development ecosystem.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Change history



Alzheimer’s disease


Alzheimer’s Management by Albumin Replacement


Disease-modifying therapy


Food and Drug Administration


Intravenous immunoglobulin


Mild cognitive impairment


Mechanism of action


Nilvadipine to Treat Alzheimer’s Disease


  1. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer’s disease. Nat Rev Dis Primers. 2015;1:15056.

    Article  PubMed  Google Scholar 

  2. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007;3(3):186–91.

    Article  PubMed  Google Scholar 

  3. Aisen P, Schneider L, Cummings J. Sympotmatic and non-amyloid/tau based pharmacologic treatment for Alzheimer’s disease. In: Selkoe D, Mandlekow E, Holtzman D, editors. The Biology of Alzheimer's Disease. New York: Cold Springs Harbor Laboratory Press; 2012. p. 511.

    Google Scholar 

  4. Boguski MS, Mandl KD, Sukhatme VP. Drug discovery. Repurposing with a difference. Science. 2009;324(5933):1394–5.

    Article  CAS  PubMed  Google Scholar 

  5. Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer’s disease discovered in repurposed agents. Dement Geriatr Cogn Disord. 2013;35(1–2):1–22.

    Article  CAS  PubMed  Google Scholar 

  6. Corbett A, Williams G, Ballard C. Drug repositioning: an opportunity to develop novel treatments for Alzheimer’s disease. Pharmaceuticals (Basel). 2013;6(10):1304–21.

    Article  CAS  PubMed  Google Scholar 

  7. Parsons CG. CNS repurposing - potential new uses for old drugs: examples of screens for Alzheimer’s disease, Parkinson’s disease and spasticity. Neuropharmacology. 2019;147:4–10.

    Article  CAS  PubMed  Google Scholar 

  8. Monacelli F, Cea M, Borghi R, Odetti P, Nencioni A. Do cancer drugs counteract neurodegeneration? Repurposing for Alzheimer’s disease. J Alzheimers Dis. 2017;55:1295–306.

    Article  PubMed  Google Scholar 

  9. Siavelis JC, Bourdakou MM, Athanasiadis EI, Spyrou GM, Nikita KS. Bioinformatics methods in drug repurposing for Alzheimer’s disease. Brief Bioinform. 2016;17(2):322–35.

    Article  CAS  PubMed  Google Scholar 

  10. Cummings J, Morstorf T, Lee G. Alzheimer’s drug-development pipeline: 2016. Alzheimers Dement (N Y). 2016;2(4):222–32.

    Article  PubMed  Google Scholar 

  11. Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K. Alzheimer’s disease drug development pipeline: 2017. Alzheimers Dement (N Y). 2017;3(3):367–84.

    Article  PubMed  Google Scholar 

  12. Cummings J, Lee G, Ritter A, Zhong K. Alzheimer’s disease drug development pipeline: 2018. Alzheimers Dement. 2018;4:195–214.

    Article  Google Scholar 

  13. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement (N Y). 2019;5:272–93.

    Article  PubMed  Google Scholar 

  14. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: Alz & Dem: TRCI 2020; 2020.

  15. Lassman SM, Shopshear OM, Jazic I, Ulrich J, Francer J. Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States. BMJ Open. 2017;7:e015110.

  16. Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at N Engl J Med. 2015;372:1031-9.

  17. Center for Drug Evaluation and Research. Drugs@FDA. U.S. Food and Drug Administration, Washington, DC. 2019. 2019. Accessed 15 Mar 2020.

  18. Hp R. Drug discovery and development. Edinburgh: Churchill Livingstone; 2006.

    Google Scholar 

  19. Scott TJ, O’Connor AC, Link AN, Beaulieu TJ. Economic analysis of opportunities to accelerate Alzheimer’s disease research and development. Ann N Y Acad Sci. 2014;1313:17–34.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Verbaanderd C, Rooman I, Meheus L, Huys I. On-label or off-label? Overcoming regulatory and financial barriers to bring repurposed medicines to cancer patients. Front Pharmacol. 2020;10:1664.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Clarke JR, Ribeiro FC, Frozza RL, De Felice FG, Lourenco MV. Metabolic dysfunction in Alzheimer’s disease: from basic neurobiology to clinical approaches. J Alzheimers Dis. 2018;64(s1):S405–S26.

    Article  PubMed  Google Scholar 

  22. Gagalo I, Rusiecka I, Kocic I. Tyrosine kinase inhibitor as a new therapy for ischemic stroke and other neurologic diseases: is there any hope for a better outcome? Curr Neuropharmacol. 2015;13(6):836–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kehoe PG. The coming of age of the angiotensin hypothesis in Alzheimer’s disease: progress toward disease prevention and treatment? J Alzheimers Dis. 2018;62(3):1443–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Candasamy M, Elhassan SA, Bhattamisra SK, Wong YH, Lim MS, Busthamin NA, Mohamad Ilni NB, Ng SS, Lim B, Ng SY, Ng WY. Type 3 diabetes (Alzheimer’s disease): new insight for promising therapeutic avenues. Panminerva Med. 2020.

  25. Ihara M, Saito S. Drug repositioning for Alzheimer’s disease: finding hidden clues in old drugs. J Alzheimers Dis. 2020;74(4):1013–28.

    Article  PubMed  Google Scholar 

  26. Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Devanand DP, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr. 2015;27(1):7–17.

    Article  PubMed  Google Scholar 

  27. Thomas T, Miners S, Love S. Post-mortem assessment of hypoperfusion of cerebral cortex in Alzheimer’s disease and vascular dementia. Brain. 2015;138:1059–69.

    Article  PubMed  Google Scholar 

  28. Sakurai H, Hanyu H, Sato T, Kume K, Hirao K, Kanetaka H, et al. Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer’s disease and cerebrovascular disease: a pilot study. Geriatr Gerontol Int. 2013;13(1):90–7.

    Article  PubMed  Google Scholar 

  29. Lee JH, Park SY, Shin HK, Kim CD, Lee WS, Hong KW. Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury. CNS Neurosci Ther. 2008;14(2):143–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ono K, Tsuji M. Pharmacological potential of cilostazol for Alzheimer’s disease. Front Pharmacol. 2019;10:559.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimers Dement. 2016;12(6):719–32.

    Article  PubMed  Google Scholar 

  32. Cerovic M, Forloni G, Balducci C. Neuroinflammation and the gut microbiota: possible alternative therapeutic targets to counteract Alzheimer’s disease? Front Aging Neurosci. 2019;11:284.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Mustapic M, Tran J, Craft S, Kapogiannis D. Extracellular vesicle biomarkers track cognitive changes following intranasal insulin in Alzheimer’s disease. J Alzheimers Dis. 2019;69(2):489–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Shoaib M, Kamal MA, Rizvi SMD. Repurposed drugs as potential therapeutic candidates for the management of Alzheimer’s disease. Curr Drug Metab. 2017;18(9):842–52.

    Article  CAS  PubMed  Google Scholar 

  35. Kumar S, Chowdhury S, Kumar S. In silico repurposing of antipsychotic drugs for Alzheimer’s disease. BMC Neurosci. 2017;18(1):76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Paranjpe MD, Taubes A, Sirota M. Insights into computational drug repurposing for neurodegenerative disease. Trends Pharmacol Sci. 2019;40(8):565–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Zhang XZ, Quan Y, Tang GY. Medical genetics-based drug repurposing for Alzheimer’s disease. Brain Res Bull. 2015;110:26–9.

    Article  CAS  PubMed  Google Scholar 

  38. Zhang M, Schmitt-Ulms G, Sato C, Xi Z, Zhang Y, Zhou Y, et al. Drug repositioning for Alzheimer’s disease based on systematic ‘omics’ data mining. PLoS One. 2016;11(12):e0168812.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Fang J, Pieper AA, Nussinov R, Lee G, Bekris L, Leverenz JB, et al. Harnessing endophenotypes and network medicine for Alzheimer’s drug repurposing. Med Res Rev. 2020. Online ahead of print.

  40. Paik H, Chung AY, Park HC, Park RW, Suk K, Kim J, et al. Repurpose terbutaline sulfate for amyotrhopic lateral sclerosis using electronic medical records. Sci Rep. 2015;5:8580.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Koenig AM, Mechanic-Hamilton D, Xie SX, Combs MF, Cappola AR, Xie L, et al. Effects of the insulin sensitizer metformin in Alzheimer disease: pilot data from a randomized placebo-controlled crossover study. Alzheimer Dis Assoc Disord. 2017;31(2):107–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, et al. IVIG treatment of mild cognitive impairment due to Alzheimer’s disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia. J Neurol Neurosurg Psychiatry. 2017;88(2):106–12.

    Article  PubMed  Google Scholar 

  43. Stonnington CM, Harel B, Locke DEC, Hentz JG, Zhang N, Maruff P, et al. Lorazepam challenge for individuals at varying genetic risk for Alzheimer disease. Alzheimer Dis Assoc Disord. 2017;31(4):271–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Lawlor B, Segurado R, Kennelly S, Olde Rikkert MGM, Howard R, Pasquier F, et al. Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial. PLoS Med. 2018;15(9):e1002660.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Boada M, Lopez O, Nunez L, Szczepiorkowski ZM, Torres M, Grifols C, et al. Plasma exchange for Alzheimer’s disease Management by Albumin Replacement (AMBAR) trial: study design and progress. Alzheimers Dement (N Y). 2019;5:61–9.

    Article  PubMed  Google Scholar 

  46. Fleminger J, Goldacre B. Prevalence of clinical trial status discrepancies: a cross-sectional study of 10,492 trials registered on both and the European Union Clinical Trials Register. PLoS One. 2018;13(3):e0193088. eCollection 2018.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Clyne B, Boland F, Murphy N, Murphy E, Moriarty F, Barry A, et al. Quality, scope and reporting standards of randomised controlled trials in Irish Health Research: an observational study. Trials. 2020;21(1):494.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Strzebonska K, Wasylewski MT, Zaborowska L, Riedel N, Wieschowski S, Stretch D, et al. Results dissemination of registered clinical trials across polish academic institutions: a cross-sectional analysis. BMJ Open. 2020;10(1):e034666.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Pillamarapu M, Mohan A, Saberwal G. An analysis of deficiencies in the data of interventional drug trials registered with clinical trials registry - India. Trials. 2019;20(1):535.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Pandolfini C, Bonati M. An audit to evaluate an Institute’s Lead Researchers’ knowledge of trial registries and to investigate adherence to data transparency issues in an Italian research institute registry. Trials. 2018;19(1):509.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burrs K, Corbett A, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40.

    Article  CAS  PubMed  Google Scholar 

  52. Cummings J, Ballard C, Tariot P, Owen R, Foff E, Youakim J, et al. Pimavanserin: potential treatment for dementia-related psychosis. J Prev Alzheimers Dis. 2018;5(4):253–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer’s dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry. 2019.

  54. Tartaglia LA. Complementary new approaches enable repositioning of failed drug candidates. Expert Opin Investig Drugs. 2006;15(11):1295–8.

    Article  CAS  PubMed  Google Scholar 

  55. Baek MC, Jung B, Kang H, Lee HS, Bae JS. Novel insight into drug repositioning: Methylthiouracil as a case in point. Pharmacol Res. 2015;99:185–93.

    Article  PubMed  Google Scholar 

Download references


Not applicable.


Not applicable.

Author information

Authors and Affiliations



GL obtained and organized the data regarding trial activity, as well as contributed to the manuscript. JB analyzed the data and was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jeffrey Cummings.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

JC has provided consultation to Acadia, Actinogen, AgeneBio, Alkahest, Alzheon, Annovis, Avanir, Axsome, Biogen, Bracket, Cassava, Cerecin, Cerevel, Cognoptix, Cortexyme, Cytox, EIP Pharma, Eisai, Foresight, Green Valley, Grifols, Hisun, Karuna, Novo Nordisk, Nutricia, Otsuka, ReMYND, Resverlogix, Roche, Samumed, Samus, Signant Health, Sunovion, Suven, Third Rock, and United Neuroscience pharmaceutical and assessment companies. JC has stock options in ADAMAS, MedAvante, QR pharma, BiOasis, and United Neuroscience. JC owns the copyright of the Neuropsychiatric Inventory. Dr. Cummings is supported by Keep Memory Alive (KMA); NIGMS grant P20GM109025; NINDS grant U01NS093334; and NIA grant R01AG053798. JB and GL have no disclosures.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised: the authors corrected the three occurrences of Dr. Jeffrey Cummings’s initial in Competing interests section from "JL" to "JC".

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bauzon, J., Lee, G. & Cummings, J. Repurposed agents in the Alzheimer’s disease drug development pipeline. Alz Res Therapy 12, 98 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: